Physician profile
Erick C Derocher
NPI 1750393260
$718.20
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $101 · 2020: $130 · 2021: $220 · 2022: $70.55 · 2023: $182 · 2024: $14.75.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $196.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $196.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $179.15 | 2019-2023 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $104.99 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $81.58 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.88 | 2020-2021 | |
| Amgen INC. | $61.06 | 2020-2023 | Otezla, Repatha |
| Kyowa Kirin, INC. | $55.82 | 2020 | |
| Lilly USA, LLC | $50.88 | 2019-2022 | |
| Glaxosmithkline, LLC. | $25.72 | 2022-2023 | Trelegy Ellipta, Shingrix |
| Janssen Pharmaceuticals, INC | $24.86 | 2020 | |
| Xeris Pharmaceuticals, INC. | $14.75 | 2024 | Gvoke Hypopen |
| Merck Sharp & Dohme LLC | $12.23 | 2020 | |
| Sanofi-Aventis U.S. LLC | $11.32 | 2021 | |
| Pfizer INC. | $11.12 | 2020 | |
| Novo Nordisk INC | $10.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erick Derocher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.